Vol 12, No 5 (October 31, 2023): Chinese Clinical Oncology

Editorial Commentary

Effective adjuvant therapy following curative hepatectomy for hepatocellular carcinoma: a myth or reality
Kelvin K. C. Ng
Chinese Clinical Oncology  
2023;
12
(5)
:46
.
 (31 October 2023) 
PDF Full Text (951) Peer Review File COI Form Open Access Get Permission
Pembrolizumab: a potential game-changer in the treatment of advanced hepatocellular carcinoma
Dmitrii Shek, Golo Ahlenstiel
Chinese Clinical Oncology  
2023;
12
(5)
:47
.
 (31 October 2023) 
PDF Full Text (1443) Peer Review File COI Form Open Access Get Permission
Could a novel category of molecular testing be emerging?
Carolina Ferraz, Laura Sterian Ward
Chinese Clinical Oncology  
2023;
12
(5)
:48
.
 (31 October 2023) 
PDF Full Text (1007) Peer Review File COI Form Open Access Get Permission
Revolutionizing hepatocellular carcinoma treatment: the advent of a new era of adjuvant therapy
Joshua Sheng Hao Lim, Vishal G. Shelat
Chinese Clinical Oncology  
2023;
12
(5)
:49
.
 (31 October 2023) 
PDF Full Text (1061) Peer Review File COI Form Open Access Get Permission

Original Article

Tislelizumab plus chemotherapy vs. pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials
Andrea Messori, Melania Rivano, Marco Chiumente, Daniele Mengato
Chinese Clinical Oncology  
2023;
12
(5)
:50
.
 (31 October 2023) 
PDF Full Text (3032) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Associations between marital quality and the prognosis of breast cancer in young Chinese women: 10.3-year median follow-up
Lili Yuan, Huilong Cai, Weiwei An, Weiguang Yuan, Eric M. Toloza, Ying Song, Jing An
Chinese Clinical Oncology  
2023;
12
(5)
:51
.
 (31 October 2023) 
PDF Full Text (2199) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access Get Permission
Expression of YAP suppresses cell proliferation and elevates the sensitivity of chemotherapy in retinoblastoma cells through lipid-peroxidation induced ferroptosis
Liting Zhong, Xuejiao Meng, Jingjing Huang, Wenwen Hao, Yajing Zuo
Chinese Clinical Oncology  
2023;
12
(5)
:52
.
 (31 October 2023) 
PDF Full Text (2536) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access Get Permission

Review Article

Assessing surrogacy using restricted mean survival time ratio for overall survival in liver cancer: a narrative review
Tiffany H. Leung, James C. Ho, Xiaofei Wang, Herbert Pang
Chinese Clinical Oncology  
2023;
12
(5)
:53
.
 (31 October 2023) 
PDF Full Text (1582) Reporting Checklist Peer Review File COI Form Open Access Get Permission
Brave new world—new and emerging treatments for gastric cancer
Emer Lynch, Austin G. Duffy, Ronan J. Kelly
Chinese Clinical Oncology  
2023;
12
(5)
:54
.
 (31 October 2023) 
PDF Full Text (2576) Peer Review File COI Form Open Access Get Permission
Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers
Binbin Zheng-Lin, Rondell P. Graham, Tanios S. Bekaii-Saab
Chinese Clinical Oncology  
2023;
12
(5)
:55
.
 (31 October 2023) 
PDF Full Text (3097) Peer Review File COI Form Open Access Get Permission
Hippocampal sparing radiation therapy for brain metastases: treatment techniques and clinical implementation
Kaley Woods, Zhilei Liu Shen, Zhengzheng Xu, Hualin Zhang, Yutaka Natsuaki, Karen Cheng, Vivian Li, Nathan Kim, Lijun Ma, Eric Chang
Chinese Clinical Oncology  
2023;
12
(5)
:56
.
 (31 October 2023) 
PDF Full Text (5709) Peer Review File COI Form Open Access Get Permission

Case Report

Boosted abscopal effect from radiotherapy and pembrolizumab in anaplastic thyroid cancer: a mini-review and case report
Doreen Goh, Kok Hing Lim, Siti Radhziah Binte Sudirman, Mei-Kim Ang, Melvin Lee Kiang Chua, Chwee Ming Lim
Chinese Clinical Oncology  
2023;
12
(5)
:57
.
 (31 October 2023) 
PDF Full Text (2791) Reporting Checklist Peer Review File COI Form Open Access Get Permission